Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Re-irradiation in Recurrent Head and Neck Squamous Cell Carcinoma
NCT07545967Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucidinostat in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicity. Started Apr 2026; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07545967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545967.